Advertisement

Hormonally Related Headaches

  • Rossella E. NappiEmail author
  • Silvia Martella
  • Grazia Sances
  • Manuela Piccinino
  • Roberta Rossini
  • Lara Tiranini
  • Emanuela Brambilla
  • Alessandro Kunder Franco
  • Alessandra Inzoli
  • Cristina Tassorelli
Chapter
Part of the ISGE Series book series (ISGE)

Abstract

Hormonally related headaches relate to reproductive milestones and to prescription of hormonal compounds for contraception, treatment of reproductive conditions, and relief of climacteric symptoms. Counseling should take into account the risk-benefit profile of the individual woman, especially when menstrual-related migraine (MRM) is diagnosed. Indeed, before prescribing exogenous hormones, it is crucial to evaluate vascular risk factors and potential impact on head pain. In addition, it is important to identify the so-called estrogen-withdrawal headache, in which head pain occurs during the hormone-free interval of hormonal contraception containing estrogens or hormonal replacement therapy (HRT). Even though some hormonal strategies may help, we still need some research to improve the knowledge about the use of estrogens and progestogens in women with hormonally related headaches.

Keywords

Migraine Headache Estrogen Progestins Combined hormonal contraception Progestogen-only contraception Vascular risk Extended regimen combined oral contraceptives Menopause Hormonal replacement therapy 

References

  1. 1.
    Genazzani AR, Gastaldi M, Bidzinska B, Mercuri N, Genazzani AD, Nappi RE, et al. The brain as a target organ of gonadal steroids. Psychoneuroendocrinology. 1992;17:385–90.CrossRefGoogle Scholar
  2. 2.
    Nappi RE, Nappi G. Neuroendocrine aspects of migraine in women. Gynecol Endocrinol. 2012;28(Suppl 1):37–41.CrossRefGoogle Scholar
  3. 3.
    Stovner L, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher A, et al. The global burden of headache: a documentation of headache prevalence and disability. Cephalalgia. 2007;27:193–210.CrossRefGoogle Scholar
  4. 4.
    Steiner TJ, Stovner LJ, Vos T. GBD 2015: migraine is the third cause of disability in under 50s. J Headache Pain. 2016;17:104.CrossRefGoogle Scholar
  5. 5.
    May A, Schulte LH. Chronic migraine: risk factors, mechanisms and treatment. Nat Rev Neurol. 2016;12:455–64.CrossRefGoogle Scholar
  6. 6.
    Stewart WF, Lipton RB, Chee E, Sawyer J, Silberstein SD. Menstrual cycle and headache in a population sample of migraineurs. Neurology. 2000;55:1517–23.CrossRefGoogle Scholar
  7. 7.
    MacGregor EA. Oestrogen and attacks of migraine with and without aura. Lancet Neurol. 2004;3:354–61.CrossRefGoogle Scholar
  8. 8.
    Martin VT, Behbehani M. Ovarian hormones and migraine headache: understanding mechanisms and pathogenesis—part 2. Headache. 2006;46:365–86.CrossRefGoogle Scholar
  9. 9.
    Martin VT, Behbehani M. Ovarian hormones and migraine headache: understanding mechanisms and pathogenesis—part I. Headache. 2006;46:3–23.CrossRefGoogle Scholar
  10. 10.
    Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd editionCephalalgia. 2018;38(1):1–211.CrossRefGoogle Scholar
  11. 11.
    Nappi G, Jensen R, Nappi RE, Sances G, Torelli P, Olesen J. Diaries and calendars for migraine. A review. Cephalalgia. 2006;26:905–16.CrossRefGoogle Scholar
  12. 12.
    MacGregor EA, Chia H, Vohrah RC, Wilkinson M. Migraine and menstruation: a pilot study. Cephalalgia. 1990;10:305–10.CrossRefGoogle Scholar
  13. 13.
    Granella F, Sances G, Zanferrari C, Costa A, Martignoni E, Manzoni GC. Migraine without aura and reproductive life events: a clinical epidemiological study in 1300 women. Headache. 1993;33:385–9.CrossRefGoogle Scholar
  14. 14.
    MacGregor EA, Hackshaw A. Prevalence of migraine on each day of the natural menstrual cycle. Neurology. 2004;63:351–3.CrossRefGoogle Scholar
  15. 15.
    Sommerville BW. Estrogen-withdrawal migraine. Neurology. 1975;25:239–44.CrossRefGoogle Scholar
  16. 16.
    Broner SW, Bobker S, Klebanoff L. Migraine in women. Semin Neurol. 2017;37:601–10.CrossRefGoogle Scholar
  17. 17.
    Brandes JL. The influence of estrogen on migraine: a systematic review. JAMA. 2006;295:1824–30.CrossRefGoogle Scholar
  18. 18.
    Pavlović JM, Allshouse AA, Santoro NF, Crawford SL, Thurston RC, Neal-Perry GS, et al. Sex hormones in women with and without migraine: evidence of migraine-specific hormone profiles. Neurology. 2016;87:49–56.CrossRefGoogle Scholar
  19. 19.
    Couturier EG, Bomhof MA, Neven AK, van Duijn NP. Menstrual migraine in a representative Dutch population sample: prevalence, disability and treatment. Cephalalgia. 2003;23:302–8.CrossRefGoogle Scholar
  20. 20.
    Granella F, Sances G, Allais G, et al. Characteristics of menstrual and non-menstrual attacks in women with menstrually-related migraine. Cephalalgia. 2004;24:707–16.CrossRefGoogle Scholar
  21. 21.
    Nappi RE, Sances G, Brundu B, Ghiotto N, Detaddei S, Biancardi C, et al. Neuroendocrine response to the serotonin agonist M-chlorophenylpiperazine in women with menstrual status migrainosus. Neuroendocrinology. 2003;78:52–60.CrossRefGoogle Scholar
  22. 22.
    Nappi RE, Sances G, Brundu B, De Taddei S, Sommacal A, Ghiotto N, et al. Estradiol supplementation modulates neuroendocrine response to M-chlorophenylpiperazine in menstrual status migrainosus triggered by oral contraception-free interval. Hum Reprod. 2005;20:3423–8.CrossRefGoogle Scholar
  23. 23.
    De Icco R, Cucinella L, De Paoli I, Martella S, Sances G, Bitetto V, et al. Modulation of nociceptive threshold by combined hormonal contraceptives in women with oestrogen-withdrawal migraine attacks: a pilot study. J Headache Pain. 2016;17:70.CrossRefGoogle Scholar
  24. 24.
    Loder E, Rizzoli P, Golub J. Hormonal management of migraine associated with menses and the menopause: a clinical review. Headache. 2007;47:329–40.CrossRefGoogle Scholar
  25. 25.
    Loder EW, Buse DC, Golub J. Headache and combination estrogen-progestin oral contraceptives: integrating evidence, guidelines, and clinical practice. Headache. 2005;45:224–31.CrossRefGoogle Scholar
  26. 26.
    MacGregor EA. Migraine and use of combined hormonal contraceptives: a clinical review. J Fam Plann Reprod Health Care. 2007;33:159–69.CrossRefGoogle Scholar
  27. 27.
    Steenland MW, Zapata LB, Brahmi D, Marchbanks PA, Curtis KM. Appropriate follow up to detect potential adverse events after initiation of select contraceptive methods: a systematic review. Contraception. 2013;87:611–24.CrossRefGoogle Scholar
  28. 28.
    Massiou H, MacGregor EA. Evolution and treatment of migraine with oral contraceptives. Cephalalgia. 2000;20:170–4.CrossRefGoogle Scholar
  29. 29.
    Aegidius K, Zwart JA, Hagen K, Schei B, Stovner LJ. Oral contraceptives and increased headache prevalence: the Head-HUNT Study. Neurology. 2006;66:349–53.CrossRefGoogle Scholar
  30. 30.
    Granella F, Sances G, Pucci E, Nappi RE, Ghiotto N, Nappi G. Migraine with aura and reproductive life events: a case control study. Cephalalgia. 2000;20:701–7.CrossRefGoogle Scholar
  31. 31.
    Curtis KM, Chrisman CE, Peterson HB, WHO Programme for Mapping Best Practices in Reproductive Health. Contraception for women in selected circumstances. Obstet Gynecol. 2002;99:1100–2.PubMedGoogle Scholar
  32. 32.
    MacGregor EA. Contraception and headache. Headache. 2013;53:247–76.CrossRefGoogle Scholar
  33. 33.
    Sacco S, Merki-Feld GS, Ægidius KL, Bitzer J, Canonico M, Kurth T, et al. European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC). Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC). J Headache Pain. 2017;18:108.CrossRefGoogle Scholar
  34. 34.
    Nappi RE, Sances G, Allais G, Terreno E, Benedetto C, Vaccaro V, et al. Effects of an estrogen-free, desogestrel-containing oral contraceptive in women with migraine with aura: a prospective diary-based pilot study. Contraception. 2011;83:223–8.CrossRefGoogle Scholar
  35. 35.
    Nappi RE, Merki-Feld GS, Terreno E, Pellegrinelli A, Viana M. Hormonal contraception in women with migraine: is progestogen-only contraception a better choice? J Headache Pain. 2013;14:66.CrossRefGoogle Scholar
  36. 36.
    Gillum LA, Mamidipudi SK, Johnston SC. Ischemic stroke risk with oral contraceptives: a meta-analysis. JAMA. 2000;284:72–8.CrossRefGoogle Scholar
  37. 37.
    MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A. Prevention of menstrual attacks of migraine: a double-blind placebo-controlled crossover study. Neurology. 2006;67:2159–63.CrossRefGoogle Scholar
  38. 38.
    Tassorelli C, Greco R, Allena M, Terreno E, Nappi RE. Transdermal hormonal therapy in perimenstrual migraine: why, when and how? Curr Pain Headache Rep. 2012;16:467–73.CrossRefGoogle Scholar
  39. 39.
    De Leo V, Scolaro V, Musacchio MC, Di Sabatino A, Morgante G, Cianci A. Combined oral contraceptives in women with menstrual migraine without aura. Fertil Steril. 2011;96:917–20.CrossRefGoogle Scholar
  40. 40.
    Sulak PJ, Kuehl TJ, Ortiz M, Shull BL. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol. 2002;18:1142–9.CrossRefGoogle Scholar
  41. 41.
    Nappi RE, Terreno E, Sances G, Martini E, Tonani S, Santamaria V, et al. Effect of a contraceptive pill containing estradiol valerate and dienogest (E2V/DNG) in women with menstrually-related migraine (MRM). Contraception. 2013;88:369–75.CrossRefGoogle Scholar
  42. 42.
    Dinger J, Do Minh T, Heinemann K. Impact of estrogen type on cardiovascular safety of combined oral contraceptives. Contraception. 2016;94:328–39.CrossRefGoogle Scholar
  43. 43.
    Sacco S, Merki-Feld GS, Ægidius KL, Bitzer J, Canonico M, Gantenbein AR, et al. European Headache Federation (EHF), the European Society of Contraception and Reproductive Health (ESCRH). Effect of exogenous estrogens and progestogens on the course of migraine during reproductive age: a consensus statement by the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESCRH). J Headache Pain. 2018;19:76.CrossRefGoogle Scholar
  44. 44.
    MacGregor EA. Migraine management during menstruation and menopause. Continuum. 2015;21:990–1003.PubMedGoogle Scholar
  45. 45.
    Nappi RE, Sances G, Detaddei S, Ornati A, Chiovato L, Polatti F. Hormonal management of migraine at menopause. Menopause Int. 2009;15:82–6.CrossRefGoogle Scholar
  46. 46.
    MacGregor EA. Migraine, menopause and hormone replacement therapy. Post Reprod Health. 2018;24:11–8.CrossRefGoogle Scholar
  47. 47.
    Nappi RE, Cagnacci A, Granella F, Piccinini F, Polatti F, Facchinetti F. Course of primary headaches during hormone replacement therapy. Maturitas. 2001;38:157–63.CrossRefGoogle Scholar
  48. 48.
    Facchinetti F, Nappi RE, Tirelli A, Polatti F, Nappi G, Sances G. Hormone supplementation differently affects migraine in postmenopausal women. Headache. 2002;42:924–9.CrossRefGoogle Scholar

Copyright information

© International Society of Gynecological Endocrinology 2019

Authors and Affiliations

  • Rossella E. Nappi
    • 1
    • 2
    Email author
  • Silvia Martella
    • 1
    • 2
  • Grazia Sances
    • 3
  • Manuela Piccinino
    • 1
  • Roberta Rossini
    • 1
  • Lara Tiranini
    • 1
    • 2
  • Emanuela Brambilla
    • 1
    • 2
  • Alessandro Kunder Franco
    • 1
    • 2
  • Alessandra Inzoli
    • 1
    • 2
  • Cristina Tassorelli
    • 3
    • 4
  1. 1.Research Center for Reproductive Medicine, Gynecological Endocrinology and MenopauseIRCCS San Matteo FoundationPaviaItaly
  2. 2.Department of Clinical, Surgical, Diagnostic and Pediatric SciencesUniversity of PaviaPaviaItaly
  3. 3.Headache Science CentreNational Neurological Institute C. MondinoPaviaItaly
  4. 4.Department of Brain and BehaviorUniversity of PaviaPaviaItaly

Personalised recommendations